Piroxicam and paracetamol in the prevention of early recurrent pain and emergency department readmission after renal colic: Randomized placebo-controlled trial

Comprehensive Summary

Jaballah et al. conducted a five-year, single-blind, randomized, placebo-controlled study across four emergency departments in Tunisia to assess whether piroxicam or paracetamol could prevent pain recurrence and unplanned ED revisits after renal colic. A total of 1,383 adults (≥18 years) discharged after renal colic were randomized to one of three 5-day regimens: one oral piroxicam daily (20 mg) plus one placebo, 2g oral paracetamol daily, or two placebos only. Recurrence was defined as moderate-to-severe pain (numeric rating scale >3/10) within 7 days of discharge, assessed by telephone follow-up. The primary outcomes were recurrence of moderate-to-severe pain and unplanned ED revisits within 7 days. Pain recurred in approximately 30% of patients across all groups, and ~22% required ED revisit, with most events occurring within the first 48 hours. However, the piroxicam group experienced significantly more adverse effects, specifically gastrointestinal, compared to the paracetamol and placebo groups. The authors concluded that neither paracetamol nor piroxicam were effective in preventing the recurrence of RC symptoms or unplanned ED revisits. Limitations of the study included evaluation of only one type of NSAID (piroxicam) which limits generalizability to other agents, and the lack of objective adherence measures.

Outcomes and Implications

This study shows that scheduled paracetamol or piroxicam after ED discharge does not reduce recurrence or revisits, highlighting the need to revise discharge practices. Rather than routine preventive prescriptions, clinicians should favor evidence-based, symptom-driven, as-needed analgesia. This approach would optimize ED resources while also avoiding unnecessary medication exposure and adverse effects.The findings highlight the need for future research into multimodal and tailored pain management strategies to reduce recurrence and ED revisits.